<div id="readability-page-1"><p>Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) have earned an average rating of &#34;Moderate Buy&#34; from the twenty-eight research firms that are  covering the company, Marketbeat reports. One research analyst  has rated the stock with a sell recommendation, four have assigned  a hold recommendation and twenty-three have assigned  a buy recommendation to  the company. The average 1-year price objective among brokers that have covered the stock in the last year is $477.4420.</p><ul><li>Alnylam Stock Soars 65%: Find Out What’s Behind the Gains</li></ul><p>A number of equities analysts recently weighed in on ALNY shares. Bank of America lifted their target price on shares of Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, September 17th. Wall Street Zen raised Alnylam Pharmaceuticals from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Monday, November 10th. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, October 8th. Citigroup raised their target price on Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, September 2nd. Finally, Oppenheimer  reissued an &#34;outperform&#34; rating and issued a $500.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, October 31st.</p><p><b>Read Our Latest Analysis on ALNY</b></p><h2>Insider Activity at Alnylam Pharmaceuticals</h2><ul><li>3 biotech powerhouses poised to thrive amid sector rebound</li></ul><p>In related news, EVP Kevin Joseph Fitzgerald sold 12,128 shares of the stock in a transaction on Monday, November 17th. The shares were sold at an average price of $452.18, for a total transaction of $5,484,039.04. Following the transaction, the executive vice president directly owned 21,264 shares of the company's stock, valued at $9,615,155.52. This represents a 36.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, CEO Yvonne Greenstreet sold 15,650 shares of the firm's stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $453.69, for a total transaction of $7,100,248.50. Following the completion of the sale, the chief executive officer owned 65,409 shares of the company's stock, valued at $29,675,409.21. The trade was a 19.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 60,328 shares of company stock worth $27,288,993 over the last ninety days. 1.50% of the stock is owned by corporate insiders. </p><h2>Institutional Trading of Alnylam Pharmaceuticals</h2><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Groupama Asset Managment raised its stake in  Alnylam Pharmaceuticals by 160.4% during the 3rd quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company's stock worth $18,610,000 after buying an additional 2,483,697 shares during the period.  Norges Bank bought a new stake in shares of  Alnylam Pharmaceuticals during the second quarter valued at approximately $662,837,000.  Arrowstreet Capital Limited Partnership raised its position in shares of  Alnylam Pharmaceuticals by 698.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company's stock worth $618,158,000 after purchasing an additional 1,185,909 shares during the period.  Qube Research &amp; Technologies Ltd bought a new position in shares of  Alnylam Pharmaceuticals in the 3rd quarter worth $369,943,000.  Finally, Holocene Advisors LP acquired a new stake in  Alnylam Pharmaceuticals in the 2nd quarter valued at $194,616,000. 92.97% of the stock is owned by institutional investors. </p><h2>Alnylam Pharmaceuticals Stock Performance</h2><ul><li>Argenx's 28% Surge &amp; Promising Product Propel Investor Confidence</li></ul><p>Shares of ALNY stock opened at $400.23 on Friday. The company has a debt-to-equity ratio of 4.45, a current ratio of 2.54 and a quick ratio of 2.49. Alnylam Pharmaceuticals has a one year low of $205.87 and a one year high of $495.55. The business's 50 day simple moving average is $446.19 and its 200 day simple moving average is $410.61. The stock has a market capitalization of $52.87 billion, a PE ratio of 1,667.63 and a beta of 0.30. </p><h2>Alnylam Pharmaceuticals Company Profile</h2> (Get Free Report)<p>Alnylam Pharmaceuticals, Inc <span>NASDAQ: ALNY<span></span></span> is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.  </p><p>Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Alnylam Pharmaceuticals</li><li>The 3 Best Retail Stocks to Shop for in August</li><li>These 3 Banks Are Rallying Into Year-End, But Will It Continue?</li><li>What is an Earnings Surprise?  </li><li>3 Surging Stocks Just Got the Ultimate Stamp of Approval From the S&amp;P 500</li><li>Why is the Ex-Dividend Date Significant to Investors?</li><li>This ETF Caught a Major Tailwind After the Fed’s Rate Cut</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxOWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxOWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Alnylam Pharmaceuticals Right Now?</h2><p>Before you consider Alnylam Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.</p><p>While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ALNY

<p>Alnylam Pharmaceuticals (NASDAQ:ALNY) has received a "Moderate Buy" rating from 28 research firms, with a 1-year price target averaging $477.44. Recent analyst upgrades include Bank of America and Citigroup, raising target prices to $520 and $583, respectively. Insider sales include EVP Kevin Fitzgerald and CEO Yvonne Greenstreet, reducing their stock ownership. Institutional investors like Groupama Asset Management and Norges Bank have increased stakes. ALNY stock opened at $400.23, with a market cap of $52.87 billion.</p>

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of "Moderate Buy" from Brokerages